SCHEMBL21323369

SCHEMBL21323369

O=C(CCc1ccc(F)cc1C(F)(F)F)N1CCC2CN(C(=O)c3ccc4[nH]nnc4c3)CC2CC1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ATXN2 Q99700 4/20 0.39
▸ ENPP2 Q13822 3/20 0.37
▸ HSD11B1 P28845 2/20 0.36
▸ RBP4 P02753 4/20 0.36
▸ DGAT2 Q96PD7 1/20 0.35
▸ HCRTR1 O43613 2/20 0.35
▸ HCRTR2 O43614 2/20 0.35
▸ GPR183 P32249 1/20 0.35
▸ CA2 P00918 1/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ ACHE P22303 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ SLC9A1 P19634 1/20 0.33
▸ NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16962750 1.00 ATXN2 (0.39) ATXN2ENPP2HSD11B1RBP4DGAT2
SCHEMBL16962449 0.89 EPHX2 (0.46) ATXN2ENPP2RBP4DGAT2MAPT
SCHEMBL21313874 0.88 ACHE (0.41) ATXN2HCRTR1HCRTR2GPR183ACHE
SCHEMBL16962635 0.86 ENPP2 (0.44) ATXN2ENPP2HSD11B1RBP4DGAT2
SCHEMBL16962636 0.86 ENPP2 (0.44) ATXN2ENPP2HSD11B1RBP4DGAT2
SCHEMBL16962634 0.86 ENPP2 (0.44) ATXN2ENPP2HSD11B1RBP4DGAT2
SCHEMBL21323193 0.84 ATXN2 (0.40) ATXN2ENPP2DGAT2CA2
SCHEMBL16963182 0.84 ATXN2 (0.40) ATXN2ENPP2DGAT2CA2
SCHEMBL21322927 0.81 GPR183 (0.40) ATXN2ENPP2HSD11B1RBP4HCRTR1
SCHEMBL16963519 0.81 GPR183 (0.40) ATXN2ENPP2HSD11B1RBP4HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900669-B1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES HOFFMANN LA ROCHE (CH) 2019-09-04 — — EP disclosed
Send feedback